Bristol-Myers Squibb Company (bmy)
BMY — Company Overview
Investors tracking BMY follow a Drug Manufacturers - General name listed on NYQ within Healthcare.
| Ticker | BMY |
| Sector | Healthcare |
| Industry | Drug Manufacturers - General |
| Exchange | NYQ |
| Market cap | $131.04B |
| Last price | $64.15 |
| Size category | Large Cap |
BMY — Business Description
The business profile of Bristol-Myers Squibb Company (BMY) reflects its role in Drug Manufacturers - General. Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers products for oncology, hematology, immunology, cardiovascular, and neuroscience indications. Its products include Opdivo for anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumors; Orencia for active rheumatoid arthritis and psoriatic arthritis; Yervoy for the treatment of unresectable or metastatic melanoma; Reblozyl to treat anemia; Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Opdualag to treat unresectable or metastatic melanoma; and Camzyos for the treatment of symptomatic obstructiv…
Official website: https://www.bms.com.
BMY — Investment Thesis
Bristol-Myers Squibb Company (BMY) attracts investors weighing Drug Manufacturers - General fundamentals against current market pricing.
- Revenue is expanding at roughly 5.7% year-over-year (public data).
- Trailing P/E of 14.04× sits in a moderate band relative to high-growth peers.
- Forward P/E (9.82×) is below trailing P/E — earnings may be expected to improve.
- Dividend yield near 4.0% adds an income component to total return.
- Equity market capitalization is approximately $131.04B.
Analyst consensus, price targets & estimates is available in Vest Terminal for Professional and Enterprise subscribers.
BMY — Financial Health
BMY financial profile reflects operating efficiency and capital structure using available market fundamentals.
Profit margin of 18.9% indicates solid bottom-line conversion. Positive free cash flow of $8.11B supports balance-sheet flexibility. Debt-to-equity of 201.86 warrants monitoring in a higher-rate environment.
| Trailing P/E | 14.04× |
| Forward P/E | 9.82× |
| Price / Sales | 2.66× |
| Price / Book | 5.87× |
| Gross margin | 71.7% |
| Operating margin | 34.4% |
| Profit margin | 18.9% |
| Return on equity | 46.6% |
| Debt / Equity | 201.86 |
| Free cash flow | $8.11B |
BMY — Growth Outlook
Growth outlook for Bristol-Myers Squibb Company (BMY) depends on demand trends in Drug Manufacturers - General and the company's ability to convert revenue into sustainable earnings.
- Revenue growth of 5.7% suggests steady but measured expansion.
- Earnings growth of 1.5% year-over-year supports improving profitability.
- Price is 5.8% below the 52-week high.
BMY — Competitive Position
Bristol-Myers Squibb Company (BMY) is evaluated against peers on scale, margin structure, and capital efficiency within Healthcare.
- Competes within Healthcare, specifically in Drug Manufacturers - General.
- Market capitalization of $131.04B places BMY among large-cap peers.
- Gross margin near 71.7% may reflect pricing power or favorable mix.
BMY — Strengths
Strengths for Bristol-Myers Squibb Company (BMY) inferred from public financial metrics:
- Revenue growth of 5.7% year-over-year.
- Earnings growth of 1.5% year-over-year.
- Return on equity near 46.6% — efficient use of shareholder capital.
- Gross margin of 71.7% supports competitive unit economics.
- Positive free cash flow ($8.11B).
- Dividend yield of 4.0% for income-oriented holders.
BMY — Weaknesses
Weaknesses and pressure points for Bristol-Myers Squibb Company (BMY) based on available data:
- Elevated debt-to-equity (201.86).
BMY — Opportunities
- Dividend yield of 4.0% appeals to total-return investors.
- Positive free cash flow enables reinvestment, debt reduction, or shareholder returns.
- Forward earnings multiple below trailing P/E — potential earnings acceleration ahead.
BMY — Risks
- Leverage (debt/equity 201.86) raises sensitivity to credit conditions.
BMY — Summary
Bristol-Myers Squibb Company (BMY) is a large-cap Healthcare company focused on Drug Manufacturers - General, listed on NYQ. Last price $64.15 with market cap $131.04B. Trailing P/E 14.04×. Revenue grew 5.7% year-over-year per public data. Notable strengths include revenue growth of 5.7% year-over-year. Key watch items include elevated debt-to-equity (201.86). For analyst estimates, ownership, and live news on BMY, upgrade to Vest Terminal Professional.
Bristol-Myers Squibb Company FAQ
What does Bristol-Myers Squibb Company (BMY) do?
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers products for oncology, hematology, immunology, cardiovascular, and neuroscience indications. Its products include Op…
What is BMY's P/E ratio?
Bristol-Myers Squibb Company has a trailing P/E of 14.04× based on publicly available market data.
Does BMY pay a dividend?
Indicated dividend yield: 4.0%. Confirm ex-dates and payout history in Vest Terminal.
What sector is BMY in?
Bristol-Myers Squibb Company is classified in Healthcare (Drug Manufacturers - General) on NYQ.
What is BMY's market capitalization?
Approximate market cap: $131.04B.
What are the main risks for BMY?
Standard market, competitive, and execution risks apply; see the Risks section.
What are the strengths of BMY?
Potential positives include revenue growth of 5.7% year-over-year, earnings growth of 1.5% year-over-year.
Where can I get analyst estimates for BMY?
Consensus estimates, price targets, and detailed analyst data for Bristol-Myers Squibb Company are available to Professional subscribers in Vest Terminal — not on this public summary page.